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Abstract. MMPs (matrix metalloproteinases), ADAMs (a 
disintegrin and metalloproteinase) and TIMPs (tissue inhibi-
tors of metalloproteinases) are implicated in invasion and 
angiogenesis: both are tissue remodeling processes involving 
regulated proteolysis of the extracellular matrix, growth factors 
and their receptors. The expression of these three groups and 
their correlations with clinical behaviour has been reported in 
gliomas but a similar comprehensive study in meningiomas 
is lacking. In this study, we aimed to evaluate the patterns of 
expression of 23 MMPs, 4 TIMPs, 8 ADAMs, selective growth 
factors and their receptors in 17 benign meningiomas using 
a quantitative real-time polymerase chain reaction (qPCR). 
Results indicated very high gene expression of 13 proteases, 
inhibitors and growth factors studied: MMP2 and MMP14, 
TIMP-1, -2 and -3, ADAM9, 10, 12, 15 and 17, EGF-R, 
EMMPRIN and VEGF-A, in almost every meningioma. 
Expression pattern analysis showed several positive correla-
tions between MMPs, ADAMs, TIMPs and growth factors. 
Furthermore, our findings suggest that expression of MMP14, 
ADAM9, 10, 12, 15 and 17, TIMP-2, EGF-R and EMMPRIN 
reflects histological subtype of meningioma such that fibro-
blastic subtype had the highest mRNA expression, transitional 
subtype was intermediate and meningothelial type had the 
lowest expression. In conclusion, this is the first comprehen-
sive study characterizing gene expression of 8 ADAMs in 
meningiomas. These neoplasms, although by histological 
definition benign, have invasive potential. Taken together, the 
selected elevated gene expression pattern may serve to identify 
targets for therapeutic intervention or indicators of biological 
progression and recurrence.
Introduction
Meningiomas are tumours of neoplastic arachnoid cap cells 
which can arise from the dura at any site. This is, however, 
most commonly the skull vault, from the skull base and at sites 
of dural reflections, whereas those which arise from the spine 
account for only 10% of meningiomas. In addition, they are 
the most frequently encountered benign, non-glial, neoplasms 
within the skull, accounting for nearly a quarter of all primary 
intracranial tumours (1) and have an estimated annual inci-
dence of 2-7 per 100,000 women and 1-5 per 100,000 men (2). 
Meningiomas are typically benign tumours but have a broad 
spectrum of clinical characteristics and histologically distinct 
subsets which are associated with high risk of recurrence, 
even after complete resection. According to the WHO clas-
sification, benign meningiomas (Grade I) have a low risk of 
recurrence and aggressive growth with 22 subtypes, including 
meningothelial, fibroblastic, transitional and psammomatous 
meningiomas. Atypical meningiomas (Grade II) are more 
likely to recur whereas anaplastic meningiomas (Grade III) 
have the greatest likelihood of recurrence and/or have more 
aggressive behaviour (3).
Although histologically benign meningiomas differ in their 
patterns of invasion from atypical meningiomas, they can still 
invade the dura, dural sinuses, skull and extracranial compart-
ments because of their ability to extend into mesenchymal 
tissues. They are not, however, considered to be atypical or 
malignant. In contrast, brain invasion is associated with recur-
rence and mortality rates similar to atypical meningiomas, even 
if the neoplasm appears to be otherwise completely benign (4).
A critical step of tumour progression and recurrence is 
the infiltrative invasion into the contiguous tissue. Metallo­
proteinases (MMPs) are a family of 23 structurally related, 
zinc-dependent endopeptidases in man. For many years, some 
of the MMPs have been widely implicated as mediators of 
invasion and angiogenesis with a role in degradation of the 
extracellular matrix (ECM). It is now evident that the func-
tions of MMPs are much more complex than was initially 
thought since they also have other roles such as regulation of 
cell adhesion (5), and control of apoptosis via release of death 
or survival factors. MMPs are also known to regulate the 
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bioavailability and/or activity of growth factors by mediating 
receptor turnover or by cleaving matrix proteins associated 
with growth factors. EMMPRIN (extracellular matrix metal-
loproteinase inducer), which is also known as CD147, basigin 
or M6, is thought to induce tumour invasion by activating 
production of various MMPs. The ability of MMP-9 to trigger 
the release of vascular endothelial growth factor (VEGF) 
which regulates angiogenesis and vascular permeability is 
also well documented (6). Additionally, the epidermal growth 
factor receptor (EGFR) family of membrane-bound receptor 
tyrosine kinases which comprise 4 structurally related recep-
tors, (EGFR, HER2, HER3/ErbB3 and HER4/ErbB4), plays 
an important role in tumour invasion (7).
The expression of some MMPs has been well studied in 
gliomas (8-12) and meningiomas (13-19) particularly in rela-
tion to invasion or recurrence. Closely related to the MMPs is 
the ADAM (a disintegrin and metalloproteinase) family which 
has also been implicated in cancer, particularly via ADAM-
mediated activation of EGFR signalling (20). ADAM8 and 
ADAM19 have also been reported to be overexpressed in 
various brain tumours (21) as well as ADAM10 in gliomas (22) 
and have been implicated in local invasion.
RECK (reversion-inducing cysteine-rich protein with kazal 
motifs) is a tumour and metastatic suppressor protein which is 
a negative regulator of MMPs and has been implicated in the 
regulation of both tumour invasion and angiogenesis. The four 
members of the tissue inhibitors of matrix metalloproteinases 
(TIMPs) family which were previously thought to be endog-
enous inhibitors of MMPs alone are now known to inhibit 
several ADAMs and to be involved independently in modula-
tion of various biological activities including cell proliferation, 
migration, invasion, angiogenesis and apoptosis (23).
Although there are several reports of elevated levels of 
some ADAMs in gliomas, there is a lack of studies for the 
co-expression of these with MMPs, TIMPs, various growth 
factors and their receptors in benign meningiomas. The aim 
of this study was to characterize RNA expression of the MMP 
family, 4 TIMPs, RECK as well as 8 ADAMs and selective 
growth factors and/or receptors implicated as modulators of 
invasion or angiogenesis as well as predictors of recurrence. 
Quantitative real-time PCR (qPCR) was used for this evalu-
ation in 17 low grade meningiomas (12 cultured cells and 5 
tissue samples) of different subtypes, including fibroblastic, 
meningothelial and transitional.
Materials and methods
Clinical samples. Seventeen low grade human meningiomas 
were studied for their profiles of MMPs, TIMPs, ADAMs 
and various growth factors and/or receptors (Table I). The 
surgical specimens used in this study were from 11 females 
and 6 males, between the age of 34 and 75, with a mean age of 
54. There were different subtypes of low grade meningiomas 
within this group of patients, generally Grade I except one 
with brain invasion (Grade II). The tumour site for the samples 
included frontal and occipital lobes as well as olfactory groove, 
cerebellopontine angle, tentorium and spinal.
The first twelve samples used (numbered 1-12, Table I) 
were cultured cells at low passages (between P2 and P6). They 
were obtained from patients undergoing surgery, under local 
Ethical permission (LREC No 00-173), from the Department 
of Neurosurgery, King's College Hospital, London in 2000 and 
2001. The tumour was diagnosed, according to the World Health 
Organisation criteria by a neuropathologist. Cells were cultured 
as monolayers in small plastic culture flasks (Marathon) at 
37˚C, 5% CO2 in a standard humidified incubator. Cells were 
routinely maintained in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with antibiotics/antimycotic at the 
final concentration of 100 IU penicillin, 100 µg amphotericin 
per ml and 10% fetal calf serum (FCS; Sigma-Aldrich).
The remaining five samples used were frozen biopsies 
(numbers 13-17, with a prefix, BT). These were collected 
between 1991 and 1997 and kindly provided by Dr Peter 
Forsyth, University of Calgary, Canada. Tissue was collected, 
under local Ethical permission, in the operating theatre imme-
diately after removal and snap frozen in liquid nitrogen. The 
meningiomas were classified and graded by a neuropathologist 
at this institution. Samples, having been previously frozen in 
liquid nitrogen, were homogenized in RNAzol, and frozen at 
­20˚C until the RNA was isolated. Dr Robert Nuttall carried 
out the qPCR at the School of Biological Sciences, University 
of East Anglia, Norwich.
RNA isolation and reverse transcription. Total RNA was 
isolated from cell culture and tissue lysates according to the 
instructions provided with the RNAzol. RNA was resuspended 
in diethyl pyrocarbonate-treated (Sigma-Aldrich) water. The 
concentrations were then determined by spectrophotometry 
using a GeneQuant pro RNA/DNA calculator (Amersham 
Pharmacia Biotech, Little Chalfont, UK). One microgram 
of total RNA was reverse transcribed using 2 µg random 
hexamers (Amersham Pharmacia Biotech) and SuperScript 
II reverse transcriptase (Life Technologies, Paisley, UK) 
according to the supplier's instructions. Complementary DNA 
copy (cDNA) was stored at ­20˚C until required for the poly-
merase chain reaction (PCR).
Quantitative real-time PCR. Sequences for 100 nM probes and 
200 nM primers used in the present study for MMPs, TIMPs, 
ADAMs, TGF-α, HB-EGF, EGF-R, erb-B2, erb-B3, VEGF-A, 
KDR and flt-1 have previously been described elsewhere 
(9,24). 18S was TaqMan® Ribosomal RNA Control reagents 
part no. 4308329 (Applied Biosystems, Warrington, UK) and 
used as an endogenous control. Briefly, PCR reactions were 
performed using the ABI Prism 7700 Sequence Detection 
system (Applied Biosystems), using the manufacturer's 
protocol. Each reaction was performed in 25 µl and contained 
the equivalent of 5 ng of reverse transcribed RNA (1 ng RNA 
for the 18S analyses), 50% TaqMan 2X PCR Master Mix 
(Applied Biosystems), 100 nM each of the forward and reverse 
primer, and 200 nM of probe. Conditions for the PCR reaction 
were 2 min at 50˚C, 10 min at 95˚C and then 40 cycles, each 
consisting of 15 sec at 95˚C, and 1 min at 60˚C. To determine 
the relative RNA levels within the samples, standard curves 
for the PCR reaction were prepared by using the cDNA from 
one sample and making 2-fold serial dilutions covering the 
range equivalent to 20-0.625 ng of RNA (for 18S analyses the 
range was from 4 to 0.125 ng). These dilutions were subject to 
real-time PCR as described above. Relative standard curves for 
cycle threshold (CT) vs. input RNA were prepared, and relative 
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levels of starting RNA in each sample were determined. The 
results for each target mRNA were normalized to those from 
18S ribosomal RNA from the same sample.
Statistical analysis. The RNA levels for each gene obtained 
from the standard curves were corrected using the 18S 
rRNA levels. All data displays and statistical analyses were 
undertaken at these ratios. To determine association between 
gene levels in the meningiomas, Spearman's rank correlation 
co­efficients (rs) were calculated between all genes regardless 
of sub-type or invasion. Rs values of >0.7 [P<0.01, (n=17)] were 
considered of potential significance. All statistical analyses 
were undertaken using statistical software Minitab v.15.1 and 
SPSS v.15.0.
Results
RNA levels for all human 23 MMPs, 4 TIMPs, RECK, 8 
ADAMs (ADAM8, 9, 10, 12, 15, 17, 19 and 28), EMMPRIN 
and growth factors and/or receptors (TGF-α, HB-EGF, EGF-R, 
erb-B2, erb-B3, VEGF-A, KDR and flt-1) were profiled in 
a series of 17 benign meningiomas. We first used the cycle 
threshold (CT) of each gene to classify its expression as not 
detected (CT=40), low (CT=36-39), moderate (CT=31-35), high 
(CT=26-30) or very high (CT=≤25) (Figs. 1 and 2).
Differential expression of MMPs and TIMPs in 17 menin-
giomas. Of all the MMPs, MMP14 (membrane-type MMP or 
MT1 MMP) was very highly expressed in all but one sample. 
Similarly, MMP2 was also very highly expressed in all the 
snap frozen tissue samples (samples 13-17) and the majority of 
cultured cells (samples 1-12) whereas MMP9 was only highly 
expressed in 5 of the latter group (Fig. 1). MMP11 and MMP19 
were highly and consistently expressed in all the meningiomas 
studied. Generally, expression of MMP26 and 27 was detected 
in a small number of meningiomas, while some of the MMPs 
(MMP8, 17, 21, 23, 24 and 25) were present in most samples 
albeit at low or moderate levels. There was limited or no 
MMP13 expression in most samples whereas none of the 
meningiomas from biopsy-derived cell cultures at low passage 
or snap frozen biopsy tissues expressed any MMP20. In addi-
tion, TIMP-1, -2 and -3 were detected at very high levels in 
every meningioma whereas TIMP-4 and RECK were gener-
ally expressed at high levels (Fig. 1).
Differential expression of ADAMs and growth factors and/
or receptors in 17 meningiomas. Given the elevated levels of 
some ADAMs reported in brain tumours, particularly gliomas, 
we quantified the RNA levels of 8 ADAMs (ADAM8, 9, 10, 
12, 15, 17, 19 and 28) in 17 meningiomas (Fig. 2). ADAM9 and 
15 were very highly expressed in every meningioma sample 
in the study whereas ADAM10, 12, 17 and 19 were either very 
highly or highly expressed in them. ADAM8 was moderately 
expressed in all except one meningioma.
We also analysed the RNA levels of a few members of the 
EGF and VEGF families (Fig. 2) to assess if there was any 
Table I. Clinical data, histological classification and anatomical site of 17 meningiomas analysed.
 Meningioma  Age
No designation Source (years) Gender Anatomical site Histological subtype WHO grade
  1 0071/01 (P4) KCH 38 Female R cerebellopontine angle Fibroblastic I
  2 0076/01 (P3) KCH 53 Female Occipital Fibroblastic I
  3 0089/01(P4) KCH 54 Female Olfactory groove Fibroblastic I
  4 0196/01 (P3) KCH 44 Male R sphenoid wing Meningiothelial-with brain invasion II
  5 0250/01 (P3) KCH 60 Female Bifrontal Meningioma-with hemangiopericytic I
      like pattern
  6 0366/01 (P3) KCH 49 Female Frontal Meningioma NOS I
  7 1177/00 (P5) KCH 45 Female Subfrontal Transitional I
  8 0191/01 (P5) KCH 69 Female Spinal Psammomatous I
  9 0208/01 (P3) KCH 51 Female Tentorium Fibroblastic-recurrent I
10 0263/01 (P3) KCH 43 Male Olfactory groove Meningiothelial I
11 0460/01 (P3) KCH 70 Female Spinal Psammomatous I
12 0461/01 (P2) KCH 34 Male Frontal Meningiothelial I
13 BT3/01 CA 52 Male R dura frontal Meningiothelial I
14 BT72 CA 75 Male L dura olfactory groove Transitional I
15 BT159 CA 37 Female L dura tentorium Meningiothelial I
16 BT294 CA 74 Male R Parietal occipital Transitional I
17 BT301 CA 71 Female L Frontal Meningiothelial I
Classification of meningiomas by tumour subtype and invasion was used for comparison purposes. The first 12 meningiomas in the table were 
short-term cell cultures derived from biopsies and obtained from King's College Hospital, London (KCH). Passage numbers are given in bold 
and in parentheses. The rest (no. 13­17 with BT as the prefix) were obtained as snap frozen biopsy samples at the time of surgery from the 
University of Calgary, Canada (CA). NOS, not otherwise specified.
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concomitant expression with MMPs, ADAMs and TIMPs. 
EGF-R, EMMPRIN and VEGF-A were very highly expressed 
whereas hbEGF was generally highly expressed in all the 
meningiomas compared to the other EGFR receptor (ErbB3), 
TGF-α, and the VEGF receptors (flt-1 or VEGFR-1 and 
flk/KDR or VEGFR2).
Patterns of gene expression in low passage cultured cells 
compared with snap frozen biopsy tissue samples. Close 
examination of the data revealed noticeable patterns in gene 
expression for selected protease, growth factor and receptor 
across different meningioma samples. For example, the snap 
frozen biopsy tissues (samples 13-17) from the University of 
Calgary showed either negligible or no expression of MMP1, 
3, 10 and 12 compared to the primary cell cultures (samples 
1-12) from King's College Hospital (Fig. 1). The reverse 
pattern was apparent with ADAM28 since all the cell cultured 
meningiomas, except one, expressed it moderately whereas all 
the snap frozen tissue samples expressed it highly. Similarly, 
flt­1 and KDR were highly expressed in the latter and mostly 
moderately expressed in the former (Fig. 2).
Figure 2. Differential expression of relative mRNA levels of 8 ADAMs, 
EMMPRIN, growth factors and their receptors in 17 meningiomas.
Figure 3. The relative mRNA expression of MMP2, MMP14 and TIMP-1, -2 
and -3 in low grade meningiomas: biopsy-derived cultured cells (1-12) and 
snap frozen tissue samples (13-17).
Figure 1. Differential expression of relative mRNA levels of all human 
MMPs, TIMPs and RECK in 17 meningiomas, as listed in Table I.
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Correlations between selected 13 elevated genes expressed in 
subtypes of meningiomas. Next, we statistically analysed the 
data to see if there were any meaningful patterns or corre-
lations for 13 selected MMPs, ADAMs, growth factors and 
receptors ( MMP2 and 14, ADAM9, 10, 12, 15 and 17, TIMP-1, 
-2 and -3, EGF-R, EMMPRIN and VEGF-A) which were very 
highly expressed. Figs. 3 and 4 show the relative RNA levels for 
individual samples while Fig. 5 represents box plots for select 
Figure 4. The relative mRNA expressions of ADAM9, 10, 12, 15 and 17, EMMPRIN, EGF-R and VEGF-A in low grade meningiomas: biopsy-derived cultured 
cells (1-12) and snap frozen tissue samples (13-17).
Figure 5. Box plots for relative mRNA values for 13 selected MMPs, ADAMs, growth factors and receptors elevated in the 3 subtypes of meningiomas: 
fibroblastic (F), meningothelial (M) and transitional (T).
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genes grouped according to meningioma subtype (fibroblastic, 
transitional and meningothelial). Relative RNA expression 
was normalized to 18S rRNA levels and is presented relative 
to normal brain sample. Although the sample size was small, 
[F (fibroblastic) n=4, T (transitional) n=3 and M (meningothe-
lial) n=6], some trends were evident, in that the fibroblastic 
subtype generally showed more expression compared with the 
meningothelial whereas the transitional showed intermediate 
expression, particularly for MMP14, ADAM9, 10, 12, 15 and 
17, TIMP­2, EGFR and EMMPRIN. Overall, the fibroblastic 
meningiomas displayed the highest median levels for 10 of the 
13 selected gene expressions as well as having the maximum 
expression in 11 out of 13 of them.
Spearman rank analysis showed that the RNA levels had 
significant correlations (Rs >0.7), between some of the MMPs, 
TIMPs, growth factors and their receptors in the meningiomas 
(Table II). The data revealed that the levels of MMP12 corre-
lated positively with MMP1, 3, 10, TIMP4 and RECK, whereas 
levels of ADAM12 correlated positively with MMP1, 3, 10, 
12, 16, TIMP4 and RECK but negatively with that of KDR. 
The levels of ADAM17 correlated with levels of ADAM9 and 
10 only; levels of ADAM15 were positively correlated with 
EGFR and negatively with levels of flt-1. ADAM28 levels 
were positively correlated with both VEGF receptors (flt­1 and 
KDR).
Discussion
Most benign meningiomas grow slowly by expansion, leading 
to compression of adjacent structures. Others vary in their 
biological characteristics, such as invasion, in that some of 
these neoplasms tend to invade brain parenchyma and bone 
because of their ability to extend into mesenchymal tissues. 
Recurrence is usually seen in classic benign meningiomas due 
to incomplete resection in contrast to atypical and anaplastic 
meningiomas, which show increased rate of proliferation and 
cord like cellular invasion into underlying brain parenchyma. 
An important biological feature of recurrence is invasion 
which is mediated by a cohort of proteases including MMPs 
and ADAMs for the degradation of a variety of extracellular 
matrix (ECM) macromolecules.
Over the last two decades, different techniques (such as 
western and northern blots, zymography and immunohisto-
chemistry) have been used to show expression of a few MMPs 
and their endogenous inhibitors, TIMPs, in brain tumours. 
However, with the advent of molecular technology, particu-
larly qPCR, comprehensive studies for the gene expression of 
a battery of MMPs, ADAMs, TIMPs and growth factors has 
become possible allowing identification of different correla-
tions and patterns associated with various biological features 
of these extrinsic brain tumours. Indeed, the discovery of 
ADAMs and changes in proposed roles of MMPs and TIMPs 
generally suggests that they may contribute to different stages 
of tumour progression by regulating cell proliferation, inva-
sion, angiogenesis and apoptosis as they are known to regulate 
growth factor activities as well as integrin function (21,25-29). 
In this study, low passage biopsy-derived cultured cells 
(samples 1-12 from King's College Hospital) were used since 
our research interest has been primarily on in vitro studies 
of tumour cell invasion. However, snap frozen biopsy tissues 
(samples 13-17 from University of Calgary) were included for 
comparative purposes.
Ubiquitous expression of a battery of MMPs has been 
reported in the literature in benign meningiomas, some of 
which have been associated with the potential to invade. The 
high or moderate expression of MMP1 and MMP12 seen in the 
cultures cells (samples 1­12) is consistent with the finding of 
other workers who have implicated them in invasion of menin-
giomas (30) and gliomas (31), respectively. Other mediators of 
invasion which are well documented include MMP2, 9 and 14. 
Notably, of the 23 MMPs studied, MMP14 was expressed very 
highly in the vast majority of meningiomas, whereas MMP9 
was expressed highly in only 5 of the low passage cultured 
cells. MMP2 was generally very highly or highly expressed. 
This finding is consistent with previous reports suggesting their 
association with the potential to invade, especially increased 
levels of MMP2 and MMP9 in Grade 1 meningiomas as prog-
nostic or predictive factors of recurrence (16,32). Moreover, 
in another study, the prognostic value of MMP9 in the risk of 
recurrence of meningiomas was investigated by analysing its 
expression in a series of meningiomas of different histological 
type and grade. It was expressed highly in 64% of them and 
was significantly associated with histological grade (18).
MMP28 (Epilysin) was highly or moderately expressed 
in every meningioma in the present study. Very recently one 
study suggested that significant elevation of MMP28 levels 
in glioblastoma patients may predict unfavorable overall 
survival (12). High expressions of MMP11 and 19 seen in all 
the meningiomas in this study are consistent with the find-
ings of previous reports using RT-PCR, western blotting and 
immunohistochemistry which indicated that they correlated 
with the WHO-grading of human malignant gliomas (11). 
Indeed, MMP19 has also been reported to be a facilitator of 
invasion in gliomas (33). This further confirms the notion that 
benign meningiomas express some of these MMPs as they 
have potential to invade like malignant gliomas. In contrast, 
MMP20 was not detected in any of the meningiomas, similar 
to previous findings with various cancers including de novo 
glioblastoma multiforme (9) and 7 established GBM cell 
lines (11).
Often results based on different methodology are not 
comparable leading to dissimilar and contradictory conclu-
sions. Nonetheless, a recent study has reviewed MMP 
expression by different methods in glioma cell cultures, estab-
lished cell lines and biopsy tissue samples and suggested that 
there is a correlation for the expression of MMP1, 2, 7, 9, 11, 
14, 15 and 25 with tumour grade. Furthermore, MMP3, 8, 10, 
13, 16, 17, 20, 21, 23, 26, 27 and 28 may not have a major role 
in tumorigenesis as some of these have limited or no expres-
sion (34).
The tissue inhibitors of MMPs, TIMP-1, -2 and -3 were 
also very highly expressed in all 17 meningiomas studied 
whereas TIMP-4 and RECK (a negative regulator of MMPs) 
were only highly expressed generally. Although TIMP-1 level 
is thought to correlate positively with histological grades of 
glioma, TIMP-4 has a negative correlation. TIMP-3 has the 
broadest spectrum for inhibition as it also inhibits several 
members of the ADAM family (35). TIMPs are now believed 
to be multifunctional proteins with some biological activities, 
which may be partially due to MMP inhibition but may also 
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be independent of MMPs, such as modulation of cell prolifera-
tion, invasion, anti-angiogenesis, pro- and anti-apoptosis (23). 
RECK (reversion-inducing cysteine-rich protein) has been 
implicated in the regulation of both tumour invasion and 
angiogenesis by inhibiting activities of MMPs 2, 9 and 14. It 
has also been shown that downregulation of the RECK gene 
is critical for invasion in T98G, a human glioblastoma cell 
line (36).
Our results also showed that all 8 ADAMs were expressed 
moderately, highly or very highly (Fig. 2). Of these, ADAMs 
9, 10, 12, 15 and 17 were very highly expressed whereas 
ADAM8 mRNA levels were moderately expressed in almost 
all the meningiomas. Due to lack of reports of ADAMs on 
meningiomas in the literature, comparison was only possible 
with studies on gliomas. Western blotting, RT-PCR and 
immunohistochemical studies have shown high expression 
of ADAM8 and ADAM19 genes in astrocytomas with a 
role in invasion (21). Overexpression of ADAM12 detected 
by RT-PCR in glioblastomas is thought to imply a role in 
proliferation through shedding of heparin-binding epidermal 
growth factor (37). It has been suggested that both ADAMs 10 
and 17 modulate tumour progression through their influence 
on distinct cellular pathways. They also regulate the activation 
of the EGFR tyrosine kinase family in the shedding of EGFR 
ligands (38).
The RNA levels of a few growth factors and their recep-
tors were also profiled in this study to determine if there was 
any correlation between their expression with that of MMPs, 
ADAMs and TIMPs. Several reports have documented that 
overexpression of epidermal growth factor receptors correlate 
with grade of malignancy in glioma. Elevated levels of EGFR 
observed in every meningioma in the present study, is consis-
tent with that demonstrated in a large cohort of meningiomas 
in which the highest degree of its expression was in benign 
meningiomas. In addition, they compared immunohistochem-
istry results to malignant meningiomas, concluding that the 
expression is inversely correlated to tumour grade and may 
serve as a potential therapeutic target with selective EGFR 
inhibitors (39).
The cytokine VEGF was originally described as vascular 
permeability factor and it functions as a positive regulator of 
angiogenesis by promoting migration, proliferation and tube 
formation of endothelial cells. The elevated levels of VEGF 
seen in this study confirm earlier reports not only on benign 
meningiomas, but atypical and malignant ones as well (40). It 
has been suggested that the increased ratio of the pro-angio-
genesis factor VEGF to the anti-angiogenic factor SEMASA 
(which is expressed in human meningiomas association with 
low microvessel density) is a negative predictor of recurrence 
in these neoplasms (41).
EMMPRIN, the extracellular MMP inducer, was also very 
highly expressed in all the meningiomas. It is thought to induce 
tumour invasion by activating MMP production (e.g. MMP1, 
2 and 15) and modulating cell-substrate adhesion processes. 
Recent reports of it have suggested positive correlation of 
EMMPRIN expression with WHO grades of both gliomas and 
meningiomas (42).
Overall, our results show a differential co-expression of 
the 44 genes studied, 13 of which were very highly expressed 
in every meningioma investigated. These include 2 of 23 
MMPs (MMP2 and 14), 3 of 4 TIMPs (TIMP-1, -2 and -3), 5 
of 8 ADAMs (ADAM9, 10, 12, 15 and 17), the growth factor 
receptor, EGF-R, the cell surface bound MMP regulator, 
EMMPRIN and the regulator of angiogenesis and vascular 
permeability, VEGF-A (Figs. 1 and 2). Normal controls for 
comparison have already been reported in our previous study 
on gene profiles in human cancer cells, including gliomas (9). 
However, distinct differences in gene expression patterns were 
consistent for both types of samples (biopsy derived cultured 
cells and snap frozen tumours). MMP1, 3, 10 and 12 were either 
absent or had low expression in the snap frozen biopsy samples 
but often highly expressed in biopsy-derived cultured cells 
(Figs. 1-4). Nevertheless, the reverse pattern was seen with 
ADAM28, vascular endothelial growth factor receptors, Flt-1 
(VEGFR-1) and KDR/Flk-1 (Kinase insert domain receptor 
or VEGFR-2) which were highly expressed in the snap frozen 
biopsy samples. This might reflect either differences in gene 
expression due to the in vitro culture conditions or the effect 
of the stroma in the expression of specific genes in the snap 
frozen samples.
It is noteworthy that due to the limited number of samples 
in the study, the data obtained for correlations must be treated 
with caution. Nonetheless, co-expression pattern analysis, 
using Spearman's rank, in the present study showed several 
positive correlations between MMPs, ADAMs, TIMPs and 
growth factors (Table II). In particular, ADAM12 correlated 
positively with a number of MMPs (MMP1, 3, 10, 12 and 16), 
TIMP4 and RECK but negatively with the VEGF receptor, 
KDR. Interestingly, the histological subtype analysis correla-
tions (Fig. 5) confirmed our previous findings on MMP­2 and 
-9 in 18 cell cultures of meningiomas using gelatin zymog-
raphy (16). With the use of RT-PCR, in this study, we found 
that the fibroblastic subtype generally showed the highest 
expression compared to the meningothelial whereas the transi-
tional showed intermediate expression for MMP14, ADAM9, 
10, 12, 15 and 17, TIMP-2, EGFR and EMMPRIN.
The presence of brain invasion is considered to predict 
aggressive clinical behaviour and recurrence. After complete 
resection, the recurrence rate in meningiomas, is estimated to 
be 10-32% within 10 years. Although factors for recurrence 
are not well understood in benign meningiomas, high levels 
of MMP9 and VEGF expression have been proposed. It was 
possible to follow up the 12 patients from King's College 
Hospital (Table I) over a period of 15 years, to evaluate if the 
overexpression of any of the genes in this study was related 
to clinical outcome. Most patients were regularly followed up 
and showed no sign of recurrence over a period of 8-15 years. 
At the time of surgical resection in 2001, patient no. 3 was 
diagnosed with brain-invasive benign meningioma (Grade II) 
but follow-up was only possible for 1 year. There was no sign 
of recurrence then. Patient no. 5 was the only one in the study 
who had recurrence in 2001, having had undergone surgery 
previously in 1995. She was free from further recurrence until 
the most recent follow-up in 2010. It was only patient no. 12 
who had a second surgery for recurrence after 14 years in 
2015. It would have been interesting to find possible links for 
recurrence with the gene expression in these patients but the 
data did not show any predictive indicators.
In conclusion, this study provides new clues about the 
molecular mechanisms implicated in this poorly characterized 
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tumour and identifies several potential targets for therapeutic 
intervention. Unlike the positive correlations seen between 
MMPs (e.g. MMP14) implicated in invasion and increased 
malignancy in glioma, this study implies that benign menin-
giomas may have the potential to invade or recur and permit 
angiogenesis. Moreover, elevated levels of TIMPs-1, -2 and 
-3 may regulate MMP proteolysis and also inhibit apoptosis. 
Taken together, the data suggest that within the tumour envi-
ronment, elevated levels of some MMPs, ADAMs, TIMPs and 
RECK may indicate that these meningiomas, although benign 
by definition, have the potential to invade and recur. The 13 
selected elevated gene expressions may serve as potential 
targets for therapeutic intervention. We can also postulate 
that our findings may support the notion that expression for 
MMP14, ADAM9, 10, 12, 15 and 17, TIMP-2, EGFR and 
EMMPRIN reflects the histological subtype of meningioma. 
Further studies include the characterising the functional role 
(and elucidating molecular mechanisms implicated) for the 
pattern of co-expression of MMPs, ADAMs, TIMPs and 
growth factors in a larger cohort of invasive and recurrent 
meningiomas.
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